Regulus Therapeutics Inc. (RGLS) financial statements (2021 and earlier)

Company profile

Business Address 10628 SCIENCE CENTER DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments34152010142133
Cash and cash equivalents34152010141413
Short-term investments     619
Prepaid expense4444445
Other current assets 011 12
Other undisclosed current assets2103100
Total current assets:40202418192539
Noncurrent Assets
Property, plant and equipment1112889
Intangible assets, net (including goodwill)0000111
Intangible assets, net (excluding goodwill)0000111
Other noncurrent assets0100000
Total noncurrent assets:22129910
TOTAL ASSETS:42212620283549
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4446749
Accounts payable1223215
Accrued liabilities1112422
Employee-related liabilities2112211
Deferred revenue00  
Debt15151515171920
Contract with customer, liability0030 
Other liabilities3323 22
Total current liabilities:22212025272631
Noncurrent Liabilities
Liabilities, other than long-term debt0101000
Contract with customer, liability000
Other liabilities0101000
Other undisclosed noncurrent liabilities    777
Total noncurrent liabilities:0101788
Total liabilities:22222126343339
Stockholders' equity
Stockholders' equity attributable to parent, including:20(0)5(6)(6)210
Common stock0000000
Additional paid in capital431406406390387386384
Accumulated other comprehensive loss     (0)(0)
Accumulated deficit(411)(406)(401)(396)(393)(384)(374)
Other undisclosed stockholders' equity attributable to parent0      
Total stockholders' equity:20(0)5(6)(6)210
TOTAL LIABILITIES AND EQUITY:42212620283549

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:0007000
Operating expenses(4)(5)(5)(10)(8)(10)(13)
Operating loss:(4)(5)(5)(3)(8)(10)(13)
Interest and debt expense(1)(1)(1)(1)(0)(1)(1)
Loss from continuing operations before equity method investments, income taxes:(5)(6)(5)(3)(8)(10)(14)
Other undisclosed income (loss) from continuing operations before income taxes0000(0)00
Loss from continuing operations before income taxes:(5)(5)(5)(3)(9)(10)(14)
Income tax expense  (0)    
Other undisclosed loss from continuing operations    (0)  
Net loss available to common stockholders, diluted:(5)(5)(5)(3)(9)(10)(14)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(5)(5)(5)(3)(9)(10)(14)
Comprehensive loss:(5)(5)(5)(3)(9)(10)(14)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    (0)00
Comprehensive loss, net of tax, attributable to parent:(5)(5)(5)(3)(9)(10)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: